Mirum Pharmaceuticals (MIRM) Stock Price, Quote, News & History | Benzinga

SPY778.570.00%QQQ751.38+0.01%BTC/USD82,612.72+0.06%DIA516.21+0.02%GLD384.50−0.02%TLT77.97−0.02%

Mirum Pharmaceuticals Inc (MIRM) Stock Price, Quote, News & History

MIRMNASDAQ

Trade with Public

Trade with Public

$86.01

4.665.73%

Last update: Oct 9, 4:00 PM

$86.01

4.665.73%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$81.01

Close

$86.01

Volume / Avg.

1.14M / 701.11K

Day Range

$81.01 - $87.79

52 Wk Range

63.23 - 130.00

Market Cap

$5.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

13.51%

Days to Cover

11.99

Recent Mirum Pharmaceuticals, Inc. News

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.

Vandana Singh

This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.

Avi Kapoor

This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.

Avi Kapoor

This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on OKLO, XE, MIRM, TILE, and TYRA.

Avi Kapoor

Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets

Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels highlight momentum and key price zones.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-227.27M

Investing Cash Flow (TTM)

-172.78M

Financing Cash Flow (TTM)

506.61M

Free Cash Flow (TTM)

-263.74M

Capital Expenditure (TTM)

-36.47M

Net Change in Cash (TTM)

106.56M

Analyst Trends and Forecast

2

Jun

2

Jul

3

Aug

3

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.61B

PE Ratio (TTM)

-

PE Ratio (FWD)

133.33

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.39

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-17.30%

Earnings Yield % (FWD)

0.75%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.16

Company Debt

Total Debt

$750.08M

LT Debt

$750.08M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$330.73M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-